What is Pantheon Vision?
Pantheon Vision is at the forefront of developing bioengineered implants designed to treat corneal blindness and restore vision globally. The company's innovative approach aims to elevate the standard of eye care by reducing the critical reliance on donated corneal tissue, which faces significant availability challenges, particularly in low- and middle-income countries (LMICs). By creating advanced bioengineered solutions, Pantheon Vision seeks to make sight restoration more accessible and sustainable worldwide.
How much funding has Pantheon Vision raised?
Pantheon Vision has raised a total of $2.5M across 1 funding round:
Angel/Seed
$2.5M
Angel/Seed (2023): $2.5M with participation from KeraLink International
Key Investors in Pantheon Vision
KeraLink International
KeraLink International is dedicated to preventing and treating corneal disease and blindness through innovative and affordable solutions, especially in low- and middle-income countries. With a focus on accessibility and sustainability, the organization aims to create lasting solutions for those at the highest risk of vision loss.
What's next for Pantheon Vision?
The recent major strategic investment signals a pivotal growth phase for Pantheon Vision, likely enabling the company to accelerate its research and development, scale manufacturing capabilities, and expand its market reach. This funding is expected to propel the advancement of their bioengineered implants, moving them closer to widespread clinical application and addressing the unmet needs of millions suffering from corneal blindness. The company's focus on LMICs suggests a strategic expansion plan targeting regions with the greatest need for accessible eye care solutions.
See full Pantheon Vision company page
